| famuyiyaov | Дата: Понедельник, 29.12.2014, 23:16 | Сообщение # 1 |
|
Группа: Гости
| Tamoxifen is an foe of the estrogen receptor in heart interweaving via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine (anti-estrogen) therapy in place of hormone receptor-positive tit cancer in pre-menopausal women, and is also a pedestal in post-menopausal women although aromatase inhibitors are also oft-times inured to in that setting.[1 -
Some tit cancer cells require estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also fix to the estrogen receptor but do not impel it. Because of this competitive discord, tamoxifen acts like a key in disrepair idle in the entangle that prevents any other indicator from being inserted, preventing estrogen from binding to its receptor. Ergo chest cancer cubicle development is blocked.
Tamoxifen was discovered during pharmaceutical convention Sovereign Chemical Industries[2 - (on occasion AstraZeneca) and is sold subordinate to the trade names Nolvadex, Istubal, and Valodex. After all, the drug, monotonous in the past its permit coming to an end, was and motionless is extensively referred to via its generic luminary "tamoxifen."
Medical uses
Heart cancer
Tamoxifen is currently used with a view the treatment of both early and advanced ER+ (estrogen receptor firm) boob cancer in pre- and post-menopausal women.[3 - Additionally, it is the most unrefined hormone treatment towards masculine tit cancer.[4 - It is also approved by the FDA quest of the prevention of breast cancer in women at steep endanger of developing the disease.[5 - It has been accessory approved for the reduction of contralateral (in the conflicting titty) cancer.
In 2006, the colossal DIVA clinical about concluded that raloxifene is equally effective in reducing the frequency of knocker cancer, but after an middling 4-year backup there were 36% fewer uterine cancers and 29% fewer blood clots in women prepossessing raloxifene than in women enchanting tamoxifen, although the diversity is not statistically significant.[6 - [7 - [8 -
In 2005, the ATAC inquisition showed that after standard in the main 68 months following a 5 year adjuvant treatment, the set that receivedanastrozole (Arimidex) had significantly sick results than the tamoxifen troupe in measures like condition on the loose survival, but no comprehensive mortality benefit.[9 - Facts from the tribulation bring up that anastrozole should be the preferred medication for postmenopausal women with localized soul cancer that is estrogen receptor (ER) positive.[10 - Another about establish that the imperil of recurrence was reduced 40% (with some imperil of bone cleavage) and that ER adversary patients also benefited from switching to anastrozole.[11 - [12 -
From http://www.fmyykj.com - suzhou pharmaceutical technology co.,ltd.
|
| |
| |
